Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Our articles on how fast semaglutide works and tirzepatide timelines can help set realistic expectations for when to expect results
Flexibility in your routine
F.JensenB
23.7% - the highest delta which I have seen so far (I added a table with a few other examples of delta between efficacy and treatment regimen estimands, which apparently correlates with drop-out rates)
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
A.YaseriM
US$ 25.83
US$ 22.12
US$ 20.40
US$ 21.93
US$ 22.98
US$ 29.65
US$ 27.48
US$ 25.51
US$ 27.88
